Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Chemotherapy-induced Nausea and Vomiting
Interventions: DRUG: Aprepitant|DRUG: Palonosetron|DRUG: Fosaprepitant
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University